Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing Into Phase 2 Clinical Development Under Multi Program Collaboration With Neurocrine Biosciences is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration ... known as Sosei Group or Sosei Heptares – has ... Read More
Forbes Press Releases
In this section, you’ll find the latest Forbes press releases and ... Richest rose by a modest 2% to US$83.4 billion this year. Forbes releases its ninth annual Under 30 Europe List ... Read More
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
We look forward to working with Bioprojet and advancing the development program for TPM ... best-in-class orexin-2 receptor agonist will extend the productive collaboration between Bioprojet ... Read More
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine Biosciences Successful ... Read More
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and ... Read More
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
The agreement will accelerate the development of this orexin-2 receptor agonist and is ... to working with Bioprojet and advancing the development program for TPM-1116 as part of our growth strategy." ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus